320 related articles for article (PubMed ID: 31729406)
21. Clinicopathologic characteristics of FBXW7-mutated colorectal adenocarcinoma and association with aberrant beta-catenin localization.
Escobar D; Bushara O; Sun L; Liao J; Yang GY
Hum Pathol; 2022 Jan; 119():51-58. PubMed ID: 34717891
[TBL] [Abstract][Full Text] [Related]
22. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
[TBL] [Abstract][Full Text] [Related]
23. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
[TBL] [Abstract][Full Text] [Related]
24. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
25. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.
Zhang J; Zheng J; Yang Y; Lu J; Gao J; Lu T; Sun J; Jiang H; Zhu Y; Zheng Y; Liang Z; Liu T
Sci Rep; 2015 Dec; 5():18678. PubMed ID: 26691448
[TBL] [Abstract][Full Text] [Related]
26. KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy.
Favazza LA; Parseghian CM; Kaya C; Nikiforova MN; Roy S; Wald AI; Landau MS; Proksell SS; Dueker JM; Johnston ER; Brand RE; Bahary N; Gorantla VC; Rhee JC; Pingpank JF; Choudry HA; Lee K; Paniccia A; Ongchin MC; Zureikat AH; Bartlett DL; Singhi AD
Mod Pathol; 2020 Sep; 33(9):1832-1843. PubMed ID: 32376853
[TBL] [Abstract][Full Text] [Related]
27. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
[TBL] [Abstract][Full Text] [Related]
28. [Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas].
Gao J; Zhang J; Lu T; Li XY; Jia N; Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):595-8. PubMed ID: 23157826
[TBL] [Abstract][Full Text] [Related]
29. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
[TBL] [Abstract][Full Text] [Related]
30. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
[TBL] [Abstract][Full Text] [Related]
31. The utility of the Ion Torrent PGM next generation sequencing for analysis of the most commonly mutated genes among patients with colorectal cancer in India.
Mehra S; Tiwari AK; Mehta SP; Sachdev R; Rajvanshi C; Chauhan R; Saini A; Vaid A
Indian J Cancer; 2022; 59(2):218-222. PubMed ID: 33753628
[TBL] [Abstract][Full Text] [Related]
32. [KRAS gene somatic mutations in Chilean patients with colorectal cancer].
Hurtado C; Encina G; Wielandt AM; Zárate AJ; Castro M; Carrillo K; Kronberg U; López-Köstner F
Rev Med Chil; 2014 Nov; 142(11):1407-14. PubMed ID: 25694286
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
[TBL] [Abstract][Full Text] [Related]
34. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
[TBL] [Abstract][Full Text] [Related]
35. [The frequency and spectrum of KRAS mutations in metastatic colorectal cancer].
Mazurenko NN; Gagarin IM; Tsyganova IV; Mochal'nikova VV; Breder VV
Vopr Onkol; 2013; 59(6):751-5. PubMed ID: 24624786
[TBL] [Abstract][Full Text] [Related]
36. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
Gao J; Sun ZW; Li YY; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
[TBL] [Abstract][Full Text] [Related]
37. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.
Kothari N; Schell MJ; Teer JK; Yeatman T; Shibata D; Kim R
J Clin Pathol; 2014 Sep; 67(9):764-7. PubMed ID: 25004944
[TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics and prognostic value of the
Yuan Y; Liu Y; Wu Y; Zhang J; Shen C; Zhang F; Wu C; Hu W
Int J Biol Markers; 2021 Jun; 36(2):33-39. PubMed ID: 34044655
[TBL] [Abstract][Full Text] [Related]
39. Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer.
Guo Y; Guo XL; Wang S; Chen X; Shi J; Wang J; Wang K; Klempner SJ; Wang W; Xiao M
Oncologist; 2020 Nov; 25(11):e1671-e1680. PubMed ID: 32627883
[TBL] [Abstract][Full Text] [Related]
40. Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component.
Li X; Sun K; Liao X; Gao H; Zhu H; Xu R
BMC Cancer; 2020 May; 20(1):400. PubMed ID: 32384877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
